Published in Naunyn Schmiedebergs Arch Pharmacol on December 05, 2007
Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. Neurosci Biobehav Rev (2009) 1.57
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull (2009) 1.45
What causes attention deficit hyperactivity disorder? Arch Dis Child (2011) 1.24
The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflugers Arch (2013) 1.02
Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull (2012) 0.97
Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov (2012) 0.97
Fitting the pieces together: current research on the genetic basis of attention-deficit/hyperactivity disorder (ADHD). Neuropsychiatr Dis Treat (2010) 0.95
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr Bull (2009) 0.93
Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology (Berl) (2013) 0.93
Gβ5-RGS complexes are gatekeepers of hyperactivity involved in control of multiple neurotransmitter systems. Psychopharmacology (Berl) (2011) 0.92
Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest (2014) 0.92
Animal models to guide clinical drug development in ADHD: lost in translation? Br J Pharmacol (2011) 0.91
Infantile parkinsonism-dystonia: a dopamine "transportopathy". J Clin Invest (2009) 0.88
Altered neurocircuitry in the dopamine transporter knockout mouse brain. PLoS One (2010) 0.86
Reinforcement, dopamine and rodent models in drug development for ADHD. Neurotherapeutics (2012) 0.84
Behavioral and pharmacological evaluation of a selectively bred mouse model of home cage hyperactivity. Behav Genet (2014) 0.81
Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. Eur J Pharmacol (2015) 0.77
Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update. Neural Plast (2012) 0.77
Reduced Dopamine Transporter Availability and Neurocognitive Deficits in Male Patients with Alcohol Dependence. PLoS One (2015) 0.76
Genome-Wide Identification, Characterization and Expression Analysis of the Solute Carrier 6 Gene Family in Silkworm (Bombyx mori). Int J Mol Sci (2016) 0.75
A new mouse model of ADHD for medication development. Sci Rep (2016) 0.75
Dopamine transporter mutant animals: a translational perspective. J Neurogenet (2016) 0.75
An Overview on the Genetics of ADHD. Xin Li Xue Bao (2008) 0.75
Incongruent reduction of dopamine transporter availability in different subgroups of alcohol dependence. Medicine (Baltimore) (2016) 0.75
Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. Elife (2017) 0.75
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (1996) 7.26
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science (1999) 4.70
Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci (2003) 4.50
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A (2001) 3.23
Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci (1998) 3.16
PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol (2001) 3.15
Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A (1998) 3.12
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol (2001) 3.11
The spectrum of behaviors influenced by serotonin. Biol Psychiatry (1998) 2.98
Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001) 2.91
Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev (2007) 2.80
Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron (2004) 2.76
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci (1995) 2.74
Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci (1998) 2.72
Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science (2004) 2.64
Modeling madness in mice: one piece at a time. Neuron (2006) 2.60
Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet (1995) 2.54
Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol (2002) 2.54
Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci (2002) 2.46
Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A (2001) 2.46
Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci U S A (2006) 2.46
Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch (2003) 2.45
Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend (1998) 2.28
Molecular characterization of the dopamine transporter. Trends Pharmacol Sci (1993) 2.28
Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol (1993) 2.25
Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 2.22
The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 2.22
Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron (2006) 2.19
Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A (2001) 2.19
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol (2001) 2.12
Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci (2003) 2.00
Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci (1990) 1.91
The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci (1995) 1.89
Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders. Neuropsychopharmacology (2005) 1.89
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol (2003) 1.79
Dopaminergic control of sleep-wake states. J Neurosci (2006) 1.77
Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci (1994) 1.71
Biochemical aspects of Parkinson's disease. Neurology (1998) 1.67
Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci (1999) 1.65
The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav (2006) 1.63
Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature (1984) 1.62
Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology (2005) 1.60
Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci (2001) 1.54
Aberrant responses in social interaction of dopamine transporter knockout mice. Behav Brain Res (2004) 1.52
Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci (1998) 1.47
Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem (1993) 1.46
Genetic animal models: focus on schizophrenia. Trends Neurosci (2001) 1.44
Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology (2004) 1.41
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci (2001) 1.40
Dopamine transporters and neuronal injury. Trends Pharmacol Sci (1999) 1.39
Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology (2005) 1.39
Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem (1997) 1.32
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol (2005) 1.31
Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev (1998) 1.31
Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods (2006) 1.28
Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry (2003) 1.28
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27
Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 1.26
MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology (1986) 1.21
Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron (1997) 1.21
Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol (1998) 1.21
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. Acta Neurol Scand Suppl (1984) 1.20
Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol (1998) 1.20
Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc Natl Acad Sci U S A (2003) 1.17
Analysis of dopamine transporter gene expression pattern -- generation of DAT-iCre transgenic mice. FEBS J (2007) 1.16
Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. Biol Psychiatry (2006) 1.15
Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry (1999) 1.15
Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci (2002) 1.13
Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol (2000) 1.13
Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences. Eur J Neurosci (2000) 1.12
Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci U S A (2001) 1.12
Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur J Neurosci (2004) 1.11
Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression. BMC Neurosci (2007) 1.09
Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem (2006) 1.07
Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci (2000) 1.07
Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem (2004) 1.07
BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry (2003) 1.06
Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol (1999) 1.06
Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol (1998) 1.05
Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience (2003) 1.04
Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci (2002) 1.04
Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev (2007) 1.04
Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology (Berl) (2001) 1.03
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res (1999) 1.02
Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. J Pharmacol Exp Ther (2003) 1.01
Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology (2006) 1.01
Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice. J Neurosci (2002) 1.01
Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci (2004) 1.00
Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry (2005) 1.00
Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol (2007) 1.00
Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J (2006) 0.99
Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology (2007) 0.98
Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mitochondria-dependent pathway. FASEB J (2005) 0.98
Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc Natl Acad Sci U S A (2004) 0.98
Mesolimbic dopamine in obesity and diabetes. Am J Physiol Regul Integr Comp Physiol (2007) 0.76